| HOME >> MEDICINE >> TECHNOLOGY |
A pharmacogenetic study of docetaxel and thalidomide in patients with androgen-independent prostate cancer (AIPC) using targeted human DMET genotyping platform -- J. Deeken, MD; Abstract #3580; June 3, 2007; 8:00am- 12:00pm; McCormick Place Convention Center, S Hall A2
A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgen-independent prostate cancer (AIPC) -- Y. Ning, MD; Abstract #5114; June 3, 2007; 2:00-6:00pm; McCormick Place Convention Center, S Hall A2
Factors predictive of outcome in relapsed, refractory MM patients treated with bortezomib, melphalan, prednisone and thalidomide (VMPT) -- A. Palumbo; Abstract #8048; June 4, 2007; 2:00-6:00pm; McCormick Place Convention Center, E451a
A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide -- C. Wu, M.D.; Abstract #9056; June 4, 2007; 2:00-6:00pm; McCormick Place Convention Center, S Hall A2
A phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG) -- G. Lesser, MD; Abstract #2067; June 4, 2007; 1:00-5:00pm; McCormick Place Convention Center, S Hall A2
Satraplatin
Oral Presentation: Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial -- C. Sternberg; Abstract #5019; June 4, 2007; 11:00-11:15am; Arie Crown Theater
Amrubicin
A randomized phase II trial of Amrubicin vs. Topotecan as
second-line treatment in extensive disease small-cell lung cancer
(SCLC) sensitive to platinum-based first line chemotherapy. -- R.M.
Jotte; Abstract
'"/>